Xenova's divestment strategy

Xenova Group plc (LSE:XEN; XNVAY) is half way on its back-to-basics mission and focusing on developing oncology products. While some companies are planning survival by broadening their technology platforms, XEN has decided that the key to its long term sustainability and value is its therapeutic pipeline.

XEN has two drug candidates that are about to enter Phase II trials. XR5000 is an inhibitor of the topoisomerase I and II enzymes that are involved in the replication of DNA during cell division and which therefore play a key role in the proliferation of cancer cells. XR9576 is a P-glycoprotein pump inhibitor being developed to restore the sensitivity of multi-drug resistant cancer cells to cytotoxic drugs...